For: | Yang M, Zhang CY. Interleukins in liver disease treatment. World J Hepatol 2024; 16(2): 140-145 [PMID: 38495285 DOI: 10.4254/wjh.v16.i2.140] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v16/i2/140.htm |
Number | Citing Articles |
1 |
Marzia Tagliaferro, Mariapaola Marino, Valerio Basile, Krizia Pocino, Gian Ludovico Rapaccini, Gabriele Ciasca, Umberto Basile, Valeria Carnazzo. New Biomarkers in Liver Fibrosis: A Pass through the Quicksand?. Journal of Personalized Medicine 2024; 14(8): 798 doi: 10.3390/jpm14080798
|
2 |
Shulin Fu, Jingyang Li, Jiarui You, Siyu Liu, Qiaoli Dong, Yunjian Fu, Ronghui Luo, Yamin Sun, Xinyue Tian, Wei Liu, Jingyi Zhang, Yu Ding, Yitian Zhang, Wutao Wang, Ling Guo, Yinsheng Qiu. Baicalin attenuates PD-1/PD-L1 axis-induced immunosuppression in piglets challenged with Glaesserella parasuis by inhibiting the PI3K/Akt/mTOR and RAS/MEK/ERK signalling pathways. Veterinary Research 2024; 55(1) doi: 10.1186/s13567-024-01355-1
|
3 |
Nouhoum Bouare, Jean Delwaide. Interleukin-mediated therapies in liver diseases and comorbidity effects. World Journal of Hepatology 2024; 16(7): 980-989 doi: 10.4254/wjh.v16.i7.980
|
4 |
Anil Khushalrao Shendge, Israel Sekler, Michal Hershfinkel. ZnR/GPR39 regulates hepatic insulin signaling, tunes liver bioenergetics and ROS production, and mitigates liver fibrosis and injury. Redox Biology 2024; 78: 103403 doi: 10.1016/j.redox.2024.103403
|